Pafuramidine

Pafuramidine (DB289) is an orally active proagent of Furamidine (HY-110137A) . Pafuramidine is a potent anti-parasitic agent, can be used to research trypanosomiasis, Pneumocystis pneumonia and malaria[1][2][3].

Product Specifications

CAS Number

[186953-56-0]

Product Name Alternative

DB289

UNSPSC

12352005

Target

Antibiotic; Parasite

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Pafuramidine.html

Purity

99.28

Solubility

DMSO : 33.33 mg/mL (ultrasonic)

Smiles

N=C(C1=CC=C(C2=CC=C(C3=CC=C(C(NOC)=N)C=C3)O2)C=C1)NOC

Molecular Formula

C20H20N4O3

Molecular Weight

364.40

References & Citations

[1]Mdachi RE, et al. Efficacy of the novel diamidine compound 2,5-Bis (4-amidinophenyl) - furan-bis-O-Methlylamidoxime (Pafuramidine, DB289) against Trypanosoma brucei rhodesiense infection in vervet monkeys after oral administration. Antimicrob Agents Chemother. 2009 Mar;53 (3) :953-7.|[2]Pohlig G, et al. Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial. PLoS Negl Trop Dis. 2016 Feb 16;10 (2) :e0004363.|[3]Chen D, et al. Pafuramidine for Pneumocystis jiroveci pneumonia in HIV-infected individuals. Expert Rev Anti Infect Ther. 2007 Dec;5 (6) :921-8.|[4]Purfield AE, et al. Interactions of DB75, a novel antimalarial agent, with other antimalarial drugs in vitro. Antimicrob Agents Chemother. 2008 Jun;52 (6) :2253-5.|[5]Mdachi RE, et al. Efficacy of the novel diamidine compound 2,5-Bis (4-amidinophenyl) - furan-bis-O-Methlylamidoxime (Pafuramidine, DB289) against Trypanosoma brucei rhodesiense infection in vervet monkeys after oral administration. Antimicrob Agents Chemother. 2009 Mar;53 (3) :953-7.